March 7, 2022
1 min read

Pharma sector expected to grow between 6 and 8 % YoY in FY23

Furthermore, most companies have sufficient headroom under debt covenants and diversified funding sources…reports Asian Lite News

India’s pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23.

Accordingly, the growth has been capped due to high base effect and inventory stocking in FY21 on account of Covid-19-led disruption in supplies of key starting materials.

Besides, API (Active Pharmaceuticals Ingredient) businesses are expected to report high single-digit growth in FY23 due to a demand uptick, the overall revenue growth is expected at 9-to-10 per cent YoY.

In a research note, India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

The agency said that higher Capex in lieu of the ‘Production-linked Incentives’ (PLI) scheme will restrict the quantum of free cash flow generation during the year.

“Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities,” the note said.

“Cost-cutting measures remain a priority for Indian companies. However, interim disruptions such as high raw material costs and logistic expenses will put pressure on the level of free cash flow generated.”

Besides, the agency said that with the significant improvement in the free cash flow generated in the near term, M&A activities will continue to provide inorganic push in FY23.

“Ind-Ra does not expect the sector’s liquidity to face a major risk, despite similar maturities levels in FY23 and FY24. Large pharma companies generally have large cash balances, which typically account for 14-16 per cent of their revenue.”

Furthermore, most companies have sufficient headroom under debt covenants and diversified funding sources.

“The interest coverage of large pharma players is likely to increase with scale and margin expansion.”

“Ind-Ra expects large pharma companies to continue with their healthy debt-funded capex and research and development programme, given higher visibility in terms of sales growth and profitability.”

ALSO READ-Tesla receives environmental nod to produce EVs at Gigafactory Berlin

Previous Story

India’s Palestine envoy found dead

Next Story

Fueling hopes and making a difference

Latest from Business

RBI Holds Rates, Boosts Outlook

One of the most significant announcements was the upward revision of India’s GDP growth forecast for FY 2025–26—from 6.5% to 6.8% In a move reflecting cautious optimism, the Reserve Bank of India

Nykaa Expands Global Footprint with UK Debut

To commemorate this significant global debut, Nykaa’s leadership hosted an exclusive soiree at the George Club in Mayfair, London Nykaa, India’s leading beauty and lifestyle destination, is set to make a grand

Nothing’s CMF Goes Indian with $100M JV

Company has announced a $100 million joint venture with Indian electronics manufacturer Optiemus Infracom Limited….reports Asian Lite News Smartphone maker Nothing has spun off its budget sub-brand CMF into an independent subsidiary,

Airbnb Boosts India Economy

Among international guests, the largest inbound sources were the United States, United Kingdom, Canada, and Australia Hospitality giant Airbnb made a significant impact on India’s economy in 2024, contributing Rs 113 billion

Rupee, Markets Gain Amid Trade Optimism

Emerging market currencies, including the rupee, have gained support amid softening in the dollar. Reports suggesting that the US economy is on the verge of a recession have contributed to the greenback’s
Go toTop